Amifostine-conjugated pH-sensitive calcium phosphate-covered magnetic-amphiphilic gelatin nanoparticles for controlled intracellular dual drug release for dual-targeting in HER-2-overexpressing breast cancer

A co-delivery strategy has been developed to achieve the synergistic effect of hydrophobic drug (CUR) and hydrophilic drug (DOX) by utilizing the unique structure of amphiphilic gelatin. An obvious contrast appeared in the tumor between HER-AGIO@CaP-CD and AGIO@CaP-CD under the IVIS imaging system after one day. Additionally, the aggregation of HER-AGIO@CaP-CD at the tumor site after a long MT may cause the slower release of drug and limit the distribution of drug at the tumor, which further affects the efficacy of the therapy.245